Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ovid Therapeutics Inc (OVID)
NASDAQ:OVID
Holding OVID?
Track your performance easily
OVID Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.68 - $4.10
Previous Close$1.25
Volume432.68K
Average Volume (3M)161.24K
Market Cap
$83.75M
Enterprise Value$22.16M
Total Cash (Recent Filing)$76.97M
Total Debt (Recent Filing)$15.39M
Price to Earnings (P/E)―
Beta1.60
Next Earnings
Nov 07, 2024EPS Estimate
-$0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding70,971,577
10 Day Avg. Volume147,781
30 Day Avg. Volume161,242
Standard Deviation0.24
R-Squared0.00790
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)1.04
Price to Sales (P/S)156.32
Price to Cash Flow (P/CF)-1.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue39.05
Enterprise Value/Gross Profit56.58
Enterprise Value/Ebitda-0.38
Forecast
1Y Price Target
$3.40Price Target Upside161.54% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Ovid Therapeutics News
PremiumCompany Announcements
Ovid Therapeutics Elevates Meg Alexander to President and COO
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentMultiple upcoming clinical development catalysts.
Financial PerformanceOvid reported 2Q’24 results including EPS of $0.12 vs consensus and estimate of -$0.21.
Organizational RestructuringOvid streamlined its workforce by eliminating 17 positions, representing 43% of its headcount.
Bears Say
Clinical TrialsTakeda-partnered soticlestat missed in both of its Ph3 studies, one in Dravet Syndrome (DS) and the other in Lennox-Gastaux Syndrome (LGS).
Valuation ImpactFollowing the failure of the soticlestat Ph3 epilepsy trials, the asset is being removed from the model.
Workforce ReductionManagement cut headcount by 17 employees, which is 43% of its workforce.
---
Ownership Overview
9.55% Insiders
8.24% Mutual Funds
0.14% Other Institutional Investors
73.56% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
OVID FAQ
What was Ovid Therapeutics Inc’s price range in the past 12 months?
Ovid Therapeutics Inc lowest stock price was $0.68 and its highest was $4.10 in the past 12 months.
What is Ovid Therapeutics Inc’s market cap?
Currently, no data Available
When is Ovid Therapeutics Inc’s upcoming earnings report date?
Ovid Therapeutics Inc’s upcoming earnings report date is Nov 07, 2024 which is 3 days ago.
How were Ovid Therapeutics Inc’s earnings last quarter?
Ovid Therapeutics Inc released its earnings results on Aug 13, 2024. The company reported $0.12 earnings per share for the quarter, beating the consensus estimate of -$0.224 by $0.344.
Is Ovid Therapeutics Inc overvalued?
According to Wall Street analysts Ovid Therapeutics Inc’s price is currently Undervalued.
Does Ovid Therapeutics Inc pay dividends?
Ovid Therapeutics Inc does not currently pay dividends.
What is Ovid Therapeutics Inc’s EPS estimate?
Ovid Therapeutics Inc’s EPS estimate is -$0.21.
How many shares outstanding does Ovid Therapeutics Inc have?
Ovid Therapeutics Inc has 70,971,580 shares outstanding.
What happened to Ovid Therapeutics Inc’s price movement after its last earnings report?
Ovid Therapeutics Inc reported an EPS of $0.12 in its last earnings report, beating expectations of -$0.224. Following the earnings report the stock price went up 4.762%.
Which hedge fund is a major shareholder of Ovid Therapeutics Inc?
Among the largest hedge funds holding Ovid Therapeutics Inc’s share is Driehaus Capital Management LLC. It holds Ovid Therapeutics Inc’s shares valued at 1M.
---
Ovid Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.40 (161.54% Upside)
$3.40 (161.54% Upside)
Blogger Sentiment
Neutral
OVID Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 1.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 1.7%
Last 30 Days ▲ 5.4%
Last 30 Days ▲ 5.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.98%
12-Months-Change
Fundamentals
Return on Equity
-29.81%
Trailing 12-Months
Asset Growth
-13.31%
Trailing 12-Months
Company Description
Ovid Therapeutics Inc
Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY.
---
OVID Stock 12 Month Forecast
Average Price Target
$3.40
▲(161.54% Upside)
Technical Analysis
Best Analysts Covering OVID
1 Year
1 Year Success Rate
10/16 ratings generated profit
1 Year Average Return
+47.91%
reiterated a buy rating 3 months ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +47.91% per trade.
---